These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
76 related articles for article (PubMed ID: 8929631)
1. Ultrastructural features and P-glycoprotein immunolocalization in Saos-2/DX580 multidrug-resistant human osteosarcoma cells. Maraldi NM; Zini N; Sabatelli P; Valmori A; Scotlandi K; Serra M; Baldini N J Submicrosc Cytol Pathol; 1996 Jan; 28(1):93-100. PubMed ID: 8929631 [TBL] [Abstract][Full Text] [Related]
2. Nuclear immunolocalization of P-glycoprotein in multidrug-resistant cell lines showing similar mechanisms of doxorubicin distribution. Baldini N; Scotlandi K; Serra M; Shikita T; Zini N; Ognibene A; Santi S; Ferracini R; Maraldi NM Eur J Cell Biol; 1995 Nov; 68(3):226-39. PubMed ID: 8603675 [TBL] [Abstract][Full Text] [Related]
3. P-glycoprotein subcellular localization and cell morphotype in MDR1 gene-transfected human osteosarcoma cells. Maraldi NM; Zini N; Santi S; Scotlandi K; Serra M; Baldini N Biol Cell; 1999 Jan; 91(1):17-28. PubMed ID: 10321019 [TBL] [Abstract][Full Text] [Related]
4. Immunocytochemical observation of multidrug resistance (MDR) p170 glycoprotein expression in human osteosarcoma cells. The clinical significance of MDR protein overexpression. Bodey B; Taylor CR; Siegel SE; Kaiser HE Anticancer Res; 1995; 15(6B):2461-8. PubMed ID: 8669809 [TBL] [Abstract][Full Text] [Related]
5. Multidrug resistance and malignancy in human osteosarcoma. Scotlandi K; Serra M; Nicoletti G; Vaccari M; Manara MC; Nini G; Landuzzi L; Colacci A; Bacci G; Bertoni F; Picci P; Campanacci M; Baldini N Cancer Res; 1996 May; 56(10):2434-9. PubMed ID: 8625324 [TBL] [Abstract][Full Text] [Related]
6. Evidence for cytoplasmic P-glycoprotein location associated with increased multidrug resistance and resistance to chemosensitizers. Abbaszadegan MR; Cress AE; Futscher BW; Bellamy WT; Dalton WS Cancer Res; 1996 Dec; 56(23):5435-42. PubMed ID: 8968098 [TBL] [Abstract][Full Text] [Related]
7. Increase of nuclear phosphatidylinositol 4,5-bisphosphate and phospholipase C beta 1 is not associated to variations of protein kinase C in multidrug-resistant Saos-2 cells. Zini N; Neri LM; Ognibene A; Scotlandi K; Baldini N; Maraldi NM Microsc Res Tech; 1997 Feb; 36(3):172-8. PubMed ID: 9080407 [TBL] [Abstract][Full Text] [Related]
8. Differentially expressed genes in multidrug resistant variants of U-2 OS human osteosarcoma cells. Chano T; Mori K; Scotlandi K; Benini S; Lapucci C; Manara MC; Serra M; Picci P; Okabe H; Baldini N Oncol Rep; 2004 Jun; 11(6):1257-63. PubMed ID: 15138564 [TBL] [Abstract][Full Text] [Related]
9. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA. Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833 [TBL] [Abstract][Full Text] [Related]
10. Establishment and characterization of multidrug-resistant human osteosarcoma cell lines. Serra M; Scotlandi K; Manara MC; Maurici D; Lollini PL; De Giovanni C; Toffoli G; Baldini N Anticancer Res; 1993; 13(2):323-9. PubMed ID: 8100126 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness of Type I interferons in the treatment of multidrug resistant osteosarcoma cells. Manara MC; Serra M; Benini S; Picci P; Scotlandi K Int J Oncol; 2004 Feb; 24(2):365-72. PubMed ID: 14719113 [TBL] [Abstract][Full Text] [Related]
12. Voacamine, an alkaloid extracted from Peschiera fuchsiaefolia, inhibits P-glycoprotein action in multidrug-resistant tumor cells. Meschini S; Marra M; Condello M; Calcabrini A; Federici E; Dupuis ML; Cianfriglia M; Arancia G Int J Oncol; 2005 Dec; 27(6):1597-603. PubMed ID: 16273216 [TBL] [Abstract][Full Text] [Related]
13. Drug resistance modification using pulsing electromagnetic field stimulation for multidrug resistant mouse osteosarcoma cell line. Hirata M; Kusuzaki K; Takeshita H; Hashiguchi S; Hirasawa Y; Ashihara T Anticancer Res; 2001; 21(1A):317-20. PubMed ID: 11299755 [TBL] [Abstract][Full Text] [Related]
14. P-glycoprotein, expressed in multidrug resistant cells, is not responsible for alterations in membrane fluidity or membrane potential. Alemán C; Annereau JP; Liang XJ; Cardarelli CO; Taylor B; Yin JJ; Aszalos A; Gottesman MM Cancer Res; 2003 Jun; 63(12):3084-91. PubMed ID: 12810633 [TBL] [Abstract][Full Text] [Related]
15. Ultrastructural changes related to multidrug resistance in CEM cells: role of cytoplasmic vesicles in drug exclusion. Bobichon H; Colin M; Depierreux C; Liautaud-Roger F; Jardillier JC J Exp Ther Oncol; 1996 Jan; 1(1):49-61. PubMed ID: 9414388 [TBL] [Abstract][Full Text] [Related]
16. The nuclear membrane in multidrug resistance: microinjection of epirubicin into bladder cancer cell lines. Featherstone JM; Speers AG; Lwaleed BA; Hayes MC; Cooper AJ; Birch BR BJU Int; 2005 May; 95(7):1091-8. PubMed ID: 15839939 [TBL] [Abstract][Full Text] [Related]
17. Osteoblastic differentiation and P-glycoprotein multidrug resistance in a murine osteosarcoma model. Takeshita H; Kusuzaki K; Murata H; Suginoshita T; Hirata M; Hashiguchi S; Ashihara T; Gebhardt MC; Mankin HJ; Hirasawa Y Br J Cancer; 2000 Apr; 82(7):1327-31. PubMed ID: 10755409 [TBL] [Abstract][Full Text] [Related]
18. P-glycoprotein, multidrug resistance and protein kinase C. Fine RL; Chambers TC; Sachs CW Stem Cells; 1996 Jan; 14(1):47-55. PubMed ID: 8820951 [TBL] [Abstract][Full Text] [Related]